Triamcinolone acetonide for intermittent treatment of sarcoidosis stage II

V. Karoukin, I. Kavalenka, L. Surkova (Minsk, Belarus)

Source: Annual Congress 2010 - Sarcoidosis: from the bench to the bedside
Session: Sarcoidosis: from the bench to the bedside
Session type: Thematic Poster Session
Number: 778
Disease area: Interstitial lung diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
V. Karoukin, I. Kavalenka, L. Surkova (Minsk, Belarus). Triamcinolone acetonide for intermittent treatment of sarcoidosis stage II. Eur Respir J 2010; 36: Suppl. 54, 778

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
LATE-BREAKING ABSTRACT: A pilot study for benign central airway stenosis: Local injection of triamcinolone acetonide therapy
Source: Annual Congress 2012 - Medical access to the pleura
Year: 2012


Comparison of two intranasal triamcinolone acetonide formulations in patients with seasonal or perennial allergic rhinitis
Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy
Year: 2008

Ethnic variation in response to intramuscular triamcinolone in children with severe therapy resistant asthma
Source: Annual Congress 2012 - Treating childhood asthma
Year: 2012

Therapy with low dose methotrexate plus diprospan in patient with recalcitrant recidivating sarcoidosis
Source: Eur Respir J 2006; 28: Suppl. 50, 541s
Year: 2006

Comparative effects of triamcinolone acetonide aqueous nasal spray (TAA) versus cetirizine (CZ) in seasonal allergic rhinitis (SAR)
Source: Eur Respir J 2001; 18: Suppl. 33, 270s
Year: 2001

Characteristics and management of patients with idiopathic pulmonary fibrosis treated with pirfenidone capsule or tablet formulation
Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries
Year: 2020


Comparison of prednisolone and budesonide in the treatment of pulmonary sarcoidosis
Source: Eur Respir J 2005; 26: Suppl. 49, 80s
Year: 2005

High-doses glucocorticosteroid treatment in sarcoidosis patients
Source: Eur Respir J 2007; 30: Suppl. 51, 118s
Year: 2007

Successful treatment of severe respiratory papillomatosis with intravenous cidofovir and interferon α-2b
Source: Eur Respir J 2002; 20: Suppl. 38, 157s
Year: 2002

Efficacy and toxicity of azathioprine plus corticosteroids in 32 patients with chronic persistent sarcoidosis
Source: Eur Respir J 2004; 24: Suppl. 48, 712s
Year: 2004

Combination therapy in severe pulmonary hypertension with bosentan and treprostinil: successful switch from subcutaneous to intravenous application
Source: Eur Respir J 2006; 28: Suppl. 50, 384s
Year: 2006

Low-dose inhaled and nasal corticosteroid use and the risk of cataracts
Source: Eur Respir J 2006; 27: 1168-1174
Year: 2006



Intravenous pulse doses of high-dose corticosteroid and cyclophosphamide in acute exacerbation of idiopathic pulmonary fibrosis
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015

Comparison of intramuscular dexamethasone with fluticasone propionate inhaler in treatment of croup
Source: Annual Congress 2009 - Diagnosis and treatment of viral respiratory infections in early childhood
Year: 2009

Combination treatment with nintedanib and prednisolone for patients with idiopathic pulmonary fibrosis
Source: International Congress 2018 – Management of idiopathic interstitial pneumonias: established and new treatments
Year: 2018

Triamcinolon acetonide nasal spray alone or in combination with loratidin in school children with severe seasonal allergic rhinitis and astma
Source: Eur Respir J 2003; 22: Suppl. 45, 284s
Year: 2003

High pulse dose steroids in Severe COVID-19 pneumonitis refractory hypoxemia to dexamethasone
Source: Virtual Congress 2021 – Highlights in COVID-19 diagnosis and treatment
Year: 2021



Phase II study of once-daily GSK573719 inhalation powder, a new long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD)
Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I
Year: 2011

Combination of pentoxifylline and steroids in sarcoidosis treatment
Source: Eur Respir J 2005; 26: Suppl. 49, 269s
Year: 2005

Aerosolized bechlometasone dipropionate (BDP) delivered via TNI® vesicles: a new approach for the treatment of asthmatic and COPD patients
Source: Eur Respir J 2002; 20: Suppl. 38, 501s
Year: 2002